ArticleScientific reports2025
Regulation of tumor hypoxic microenvironment by cyanobacteria-photosensitizer hybrid bioplatform for enhanced photodynamic therapy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Synergistic disruption of redox and energy homeostasis via high-entropy layered double hydroxide nanozymes for enhanced tumor therapy.iScience · 2026Article
- Advancing psoriasis therapy through oxygen-boosted dual-section microneedle technology.Acta pharmaceutica Sinica. B · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Tumor hypoxic microenvironments limit the generation efficiency of reactive oxygen species (ROS) in photodynamic therapy (PDT) and exacerbate immune suppression, severely restricting its clinical efficacy. To overcome this bottleneck, this study developed a bio-organic hybrid delivery system based on oxygen-producing cyanobacteria and nano-photosensitizers (PCC7942@ICG-NPs), which synergistically enhances efficacy through in situ oxygen delivery and augment ROS. Specifically, indocyanine green (ICG) was loaded onto bovine serum albumin (BSA) via hydrophobic interactions to form stable nanoparticles (ICG-NPs), and the positively charged surface of the nanoparticles enabled efficient self-assembly with the oxygen-producing cyanobacterium PCC7942 by electrostatic interactions. Upon near-infrared laser activation, the cyanobacteria continuously release molecular oxygen through photosynthesis, significantly increasing the local tumor oxygen partial pressure (pO₂), which potentiates ICG-mediated photodynamic therapeutic efficacy and boosts ROS production, simultaneously improving the tumor hypoxic microenvironment and triggering systemic antitumor immunity. This work provides an innovative strategy to overcome tumor hypoxia and combined PDT therapy, showing significant clinical translation potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.